The size of the Prostate Cancer Market in the Asia Pacific was valued at USD 10.36 billion in 2019 and Expected to grow at a CAGR of 10.65%, to reach USD 17.18 billion by 2024 during the forecast period 2019-2024.
Prostate cancer is a common term used for the diseased situations in which abnormal cells grow and infect in an uncontrolled manner in the prostate. New product inventions, partnership agreements, collaborations, and acquisitions are some of the key strategies adopted by the players to get a large market share in the forecast period.
Advancement in technology, personalized medicine, cost-effective treatment procedures are a few other factors expected to provide a boost to the Asia-Pacific prostate cancer market. Rising incidence of prostate cancers and the availability of various treatment modalities are also fuelling market growth. However, limited commercially availability drugs and treatments for this cancer is the challenge restraining the growth of the prostate cancer market. Asia Pacific market is estimated to show a substantial growth rate due to the presence of high unmet needs in promising countries.
Asia Pacific Prostate Cancer Market segmented and sub-segmented into the following categories.
On the basis of region, China and India are estimated to grow at the highest rate due to the increasing cancer population.
Key Companies leading the Asia Pacific Prostate Cancer Market Profiled in the Report are Sanofi S.A, GlaxoSmithKline, AstraZeneca, AbbVie, Varian Medical Systems, Elekta, Theragenics, Pfizer, Novartis, Roche, Bayer, Johnson & Johnson, Abbott Laboratories, and Genentech, etc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Diagnostic Techniques
5.1.1 Introduction
5.1.2 Digital Rectal Exam (DRE)
5.1.3 Prostate Specific Antigen Test (PSA)
5.1.4 Y-o-Y Growth Analysis, By Product
5.1.5 Market Attractiveness Analysis, By Product
5.1.6 Market Share Analysis, By Product
5.2 Surgery
5.2.1 Introduction
5.2.2 Radical Prostatectomy
5.2.3 Orchidectomy
5.2.4 Trans Urethral Resection (TUR)
5.2.5 Y-o-Y Growth Analysis, By Type
5.2.6 Market Attractiveness Analysis, By Type
5.2.7 Market Share Analysis, By Type
5.3 Radiation Therapy
5.3.1 Introduction
5.3.2 External Beam Radiation Therapy
5.3.2.1 3D Conformal Radiation Therapy
5.3.2.2 Intensity Modulated Radiation Therapy
5.3.2.3 Stereotactic Body Radiation Therapy
5.3.2.4 Proton Beam Radiation Therapy
5.3.3 Brachytherapy
5.3.3.1 Permanent Brachytherapy
5.3.3.2 Temporary Brachytherapy
5.3.4 Y-o-Y Growth Analysis, By Application
5.3.5 Market Attractiveness Analysis, By Application
5.3.6 Market Share Analysis, By Application
5.4 Chemotherapy
5.4.1 Introduction
5.4.2 Docetaxel
5.4.3 Etoposide
5.4.4 Vinblastine
5.4.5 Carboplatin
5.4.6 Vinorelbine
5.4.7 Y-o-Y Growth Analysis, By Disease Indications
5.4.8 Market Attractiveness Analysis, By Disease Indications
5.4.9 Market Share Analysis, By Disease Indications
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Diagnostic Techniques
6.1.3.3 By Surgery
6.1.3.4 By Radiation Therapy
6.1.3.5 By Chemotherapy
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Diagnostic Techniques
6.1.4.3 By Surgery
6.1.4.4 By Radiation Therapy
6.1.4.5 By Chemotherapy
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Diagnostic Techniques
6.1.5.3 By Surgery
6.1.5.4 By Radiation Therapy
6.1.5.5 By Chemotherapy
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Sanofi S.A
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 GlaxoSmithKline
8.3 AstraZeneca
8.4 AbbVie
8.5 Varian Medical Systems
8.6 Elekta
8.7 Theragenics
8.8 Pfizer
8.9 Novartis
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
